Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter A Crooks

Showing results (291-300 of 319) with videos related to

Pageof 32
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|September 1, 2010
The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in ratsJoshua S Beckmann, Kiran B Siripurapu, Justin R Nickell, et al.
Pharmacology Research & Perspectives|June 23, 2018
Evaluation of morphine-like effects of the mixed mu/delta agonist morphine-6-<i>O</i>-sulfate in rats: Drug discrimination and physical dependenceJai Shankar K Yadlapalli, Shoban Babu Bommagani, Ryan D Mahelona, et al.
Bioorganic & Medicinal Chemistry Letters|March 31, 2004
Development of subtype-selective ligands as antagonists at nicotinic receptors mediating nicotine-evoked dopamine releasePeter A Crooks, Joshua T Ayers, Rui Xu, et al.
International Journal of Radiation Oncology, Biology, Physics|July 19, 2014
Targeting nucleophosmin 1 represents a rational strategy for radiation sensitizationKonjeti R Sekhar, Mouadh Benamar, Amudhan Venkateswaran, et al.
Frontiers in Pharmacology|May 25, 2023
Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in ratsVenumadhav Janganati, Paloma Salazar, Brian J Parks, et al.
International Journal of Molecular Sciences|October 13, 2021
Biobanked Glioblastoma Patient-Derived Organoids as a Precision Medicine Model to Study Inhibition of InvasionEmilie Darrigues, Edward H Zhao, Annick De Loose, et al.
Pharmaceuticals (Basel, Switzerland)|October 28, 2023
Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and Extend <i>C. elegans</i> Life- and HealthspanSamuel Kakraba, Srinivas Ayyadevara, Nirjal Mainali, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 31, 2008
KDOQI US commentary on the KDIGO clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in CKDCraig E Gordon, Ethan M Balk, Bryan N Becker, et al.
Neurochemical Research|August 1, 2015
r-bPiDI, an α6β2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine ReinforcementJoshua S Beckmann, Andrew C Meyer, M Pivavarchyk, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 24, 2010
meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine releaseDavid B Horton, Kiran B Siripurapu, Seth D Norrholm, et al.
Pageof 32

Showing results (291-300 of 319) with videos related to

Sort By:
Pageof 32
The Journal of Pharmacology and Experimental Therapeutics|September 1, 2010
The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in ratsJoshua S Beckmann, Kiran B Siripurapu, Justin R Nickell, et al.
Pharmacology Research & Perspectives|June 23, 2018
Evaluation of morphine-like effects of the mixed mu/delta agonist morphine-6-<i>O</i>-sulfate in rats: Drug discrimination and physical dependenceJai Shankar K Yadlapalli, Shoban Babu Bommagani, Ryan D Mahelona, et al.
Bioorganic & Medicinal Chemistry Letters|March 31, 2004
Development of subtype-selective ligands as antagonists at nicotinic receptors mediating nicotine-evoked dopamine releasePeter A Crooks, Joshua T Ayers, Rui Xu, et al.
International Journal of Radiation Oncology, Biology, Physics|July 19, 2014
Targeting nucleophosmin 1 represents a rational strategy for radiation sensitizationKonjeti R Sekhar, Mouadh Benamar, Amudhan Venkateswaran, et al.
Frontiers in Pharmacology|May 25, 2023
Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in ratsVenumadhav Janganati, Paloma Salazar, Brian J Parks, et al.
International Journal of Molecular Sciences|October 13, 2021
Biobanked Glioblastoma Patient-Derived Organoids as a Precision Medicine Model to Study Inhibition of InvasionEmilie Darrigues, Edward H Zhao, Annick De Loose, et al.
Pharmaceuticals (Basel, Switzerland)|October 28, 2023
Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and Extend <i>C. elegans</i> Life- and HealthspanSamuel Kakraba, Srinivas Ayyadevara, Nirjal Mainali, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 31, 2008
KDOQI US commentary on the KDIGO clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in CKDCraig E Gordon, Ethan M Balk, Bryan N Becker, et al.
Neurochemical Research|August 1, 2015
r-bPiDI, an α6β2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine ReinforcementJoshua S Beckmann, Andrew C Meyer, M Pivavarchyk, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 24, 2010
meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine releaseDavid B Horton, Kiran B Siripurapu, Seth D Norrholm, et al.
Pageof 32